Practice-changing updates in CLL from ASH 2024: findings from the AMPLIFY trial
Piers Patten, MB ChB, MRCP, FRCPath, PhD, King's College London, London, UK, discusses the potentially practice-changing updates in chronic lymphocytic leukemia (CLL) from ASH 2024. He highlights the AMPLIFY trial (NCT03836261), which showed promising outcomes for the combination of acalabrutinib and venetoclax in the front line. Dr Patten notes that discussions on licensing and reimbursement will take place over the next few months, but he is optimistic about the potential for this regimen to become available in the NHS. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.